Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Michael Stalhamer has 1 pending office action in Biotechnology & Pharmaceuticals. The portfolio is represented by 1 distinct examiner and 1 distinct art unit, so the recorded prosecution activity follows one examination path.
MEYERING, SHABANA SHABBEER is the busiest examiner, with 1 pending matter. Counsel can direct immediate review toward that examiner’s action and tailor the response to the applicable biotechnology and pharmaceutical examination context.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEYERING, SHABANA SHABBEER | 1 | 67.6% | +46.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040803 | NUCLEIC ACID THERAPY FOR DIFFERENTIAL MODULATION OF HOST MICROFLORA | MEYERING, SHABANA SHABBEER | 19d |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18040803 | NUCLEIC ACID THERAPY FOR DIFFERENTIAL MODULATION OF HOST MICROFLORA | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | 19d | Pending | Feb 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMichael Stalhamer has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Shabana Shabbeer Meyering has the most, with 1 of Michael Stalhamer's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.